-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Upgrades Evolent Health to Buy, Lowers Price Target to $6

Benzinga·08/11/2026 12:19:20
Listen to the news
Citigroup analyst Daniel Grosslight upgrades Evolent Health (NYSE:EVH) from Neutral to Buy and lowers the price target from $6.75 to $6.